Clinical Trial Update: Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sequential intranodal immunotherapy with anti-PD1 pembrolizumab in follicular lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Intranodal immunotherapy (SIIT)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Oslo University Hospital | Conditions: Follicular Lymphoma | Phase 2 | Status: COMPLETED